These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 31079947)
61. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Zhu FC; Liang ZL; Li XL; Ge HM; Meng FY; Mao QY; Zhang YT; Hu YM; Zhang ZY; Li JX; Gao F; Chen QH; Zhu QY; Chu K; Wu X; Yao X; Guo HJ; Chen XQ; Liu P; Dong YY; Li FX; Shen XL; Wang JZ Lancet; 2013 Mar; 381(9871):1037-45. PubMed ID: 23352749 [TBL] [Abstract][Full Text] [Related]
63. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study. Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003 [TBL] [Abstract][Full Text] [Related]
64. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Kamtchoua T; Bologa M; Hopfer R; Neveu D; Hu B; Sheng X; Corde N; Pouzet C; Zimmermann G; Gurunathan S Vaccine; 2013 Jan; 31(2):327-33. PubMed ID: 23153437 [TBL] [Abstract][Full Text] [Related]
66. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Bines JE; Danchin M; Jackson P; Handley A; Watts E; Lee KJ; West A; Cowley D; Chen MY; Barnes GL; Justice F; Buttery JP; Carlin JB; Bishop RF; Taylor B; Kirkwood CD; Lancet Infect Dis; 2015 Dec; 15(12):1389-97. PubMed ID: 26318715 [TBL] [Abstract][Full Text] [Related]
67. Safety, tolerability and immunogenicity of an active anti-Aβ Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Pérez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleón I; San-José I; Munuera J; Rodríguez-Gómez O; Abdelnour C; Lafuente A; Buendía M; Boada M; Tárraga L; Ruiz A; Sarasa M Alzheimers Res Ther; 2018 Jan; 10(1):12. PubMed ID: 29378651 [TBL] [Abstract][Full Text] [Related]
68. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Novak P; Schmidt R; Kontsekova E; Zilka N; Kovacech B; Skrabana R; Vince-Kazmerova Z; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Winblad B; Novak M Lancet Neurol; 2017 Feb; 16(2):123-134. PubMed ID: 27955995 [TBL] [Abstract][Full Text] [Related]
69. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. McCarty JM; Lock MD; Hunt KM; Simon JK; Gurwith M Vaccine; 2018 Feb; 36(6):833-840. PubMed ID: 29317118 [TBL] [Abstract][Full Text] [Related]
70. Preclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli Infections. Chorro L; Li Z; Chu L; Singh S; Gu J; Kim JH; Dutta K; Pan R; Kodali S; Ndreu D; Patel A; Hawkins JC; Ponce C; Silmon de Monerri N; Keeney D; Illenberger A; Jones CH; Andrew L; Lotvin J; Prasad AK; Kanevsky I; Jansen KU; Anderson AS; Donald RGK Infect Immun; 2022 Apr; 90(4):e0002222. PubMed ID: 35311580 [TBL] [Abstract][Full Text] [Related]
71. Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trials. Zhu FC; Zeng H; Li JX; Wang B; Meng FY; Yang F; Gu J; Liang HY; Hu YM; Liu P; Peng LS; Hu XK; Zhuang Y; Fan M; Li HB; Tan ZM; Luo P; Zhang P; Chu K; Zhang JY; Zeng M; Zou QM Vaccine; 2022 May; 40(23):3216-3227. PubMed ID: 35473663 [TBL] [Abstract][Full Text] [Related]
72. A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose. Treanor J; Sherwood J; Cramer JP; Le Cam Bouveret N; Lin S; Baehner F; Borkowski A; Vaccine; 2020 Aug; 38(36):5842-5850. PubMed ID: 32563606 [TBL] [Abstract][Full Text] [Related]
77. A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years. Remich S; Kitchin N; Peterson J; Li P; Pride MW; Brock L; Anderson AS; Gruber WC; Jansen KU; Lockhart SP; Webber C J Infect Dis; 2024 Feb; 229(2):367-375. PubMed ID: 37531657 [TBL] [Abstract][Full Text] [Related]
78. A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI. Fierro CA; Sarnecki M; Spiessens B; Go O; Day TA; Davies TA; van den Dobbelsteen G; Poolman J; Abbanat D; Haazen W NPJ Vaccines; 2024 Jun; 9(1):106. PubMed ID: 38877036 [TBL] [Abstract][Full Text] [Related]
79. Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections. Saade E; Gravenstein S; Donskey CJ; Wilson B; Spiessens B; Abbanat D; Poolman J; de Palacios PI; Hermans P Vaccine; 2020 Jul; 38(33):5100-5104. PubMed ID: 32561123 [TBL] [Abstract][Full Text] [Related]
80. A phase I/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine. Low JG; de Alwis R; Chen S; Kalimuddin S; Leong YS; Mah TKL; Yuen N; Tan HC; Zhang SL; Sim JXY; Chan YFZ; Syenina A; Yee JX; Ong EZ; Sekulovich R; Sullivan BB; Lindert K; Sullivan SM; Chivukula P; Hughes SG; Ooi EE NPJ Vaccines; 2022 Dec; 7(1):161. PubMed ID: 36513697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]